title: [Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health)].
abstract: The TORCH study (Towards a Revolution in COPD Health) was a double-blind, randomised, placebo-controlled clinical trial, investigating the combination of salmeterol/fluticasone propionate for 3 years in COPD. The primary end point was on all-cause mortality. Secondary end points included COPD exacerbation rate, lung function and health status. More than 6000 patients were randomised. In this article, we briefly report the most significant results of the study. The efficacy on mortality (reduction of the risk of death of 17.5%) was near the predetermined level of statistical significance (p = 0.052); the combination had a significant effect on the three pillars of COPD management, that is: improvement of quality of life and respiratory function, and reduction of the rate of exacerbations. In addition to being effective, the combination salmeterol/fluticasone (50/500 microg 2x/day) is well tolerated in COPD and had a favourable benefit/risk ratio.
authors.affiliation: Service de Pneumologie, CHU Sart-Tilman, Liège, Belgique. jlcorhay@chu.ulg.ac.be
authors.forename: J L
authors.initials: JL
authors.lastname: Corhay
authors.forename: R
authors.initials: R
authors.lastname: Louis
mesh_terms: D000368:Aged; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000730:Androstadienes / Q000008:administration & dosage / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002423:Cause of Death; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D000068298:Fluticasone; D005500:Follow-Up Studies; D006304:Health Status; D006801:Humans; D008168:Lung / Q000187:drug effects / Q000503:physiopathology; D008297:Male; D008449:Maximal Expiratory Flow-Volume Curves / Q000187:drug effects; D010919:Placebos; D011446:Prospective Studies; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000503:physiopathology; D011788:Quality of Life; D018570:Risk Assessment; D000068299:Salmeterol Xinafoate; D015996:Survival Rate; D014797:Vital Capacity / Q000187:drug effects
chemical_list: D000730:Androstadienes; D001993:Bronchodilator Agents; D004338:Drug Combinations; D010919:Placebos; D000068299:Salmeterol Xinafoate; D000068298:Fluticasone; D000420:Albuterol